Retrospective Analysis of the Starting Dose of Combined ICS/LABA for Cough-variant Asthma and Cough-predominant Asthma

• Published in: In vivo (Athens) Vol. 36; no. 2; pp. 949 - 953
• Main Authors: Nakajima, Takeo, Nagano, Tatsuya, Nishimura, Yoshihiro
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.03.2022
• Subjects: Administration, Inhalation; Adrenal Cortex Hormones - therapeutic use; Anti-Asthmatic Agents - therapeutic use; Asthma - complications; Asthma - diagnosis; Asthma - drug therapy; Cough - drug therapy; Cough - etiology; Drug Therapy, Combination; Humans; Retrospective Studies; cough variant asthma; cough predominant asthma; Cough; combination of inhaled corticosteroid and bronchodilator
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.12785

Although the usefulness of inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) in cough-variant asthma and cough-predominant asthma has been reported, there is no consensus on its starting dose. The aim of this study is to find the optimal dose of ICS/LABA for cough-variant asthma and cough-predominant asthma. We analysed 112 patients who visited our clinic from January 2009 to December 2012 with the chief complaint of cough that had continued for more than 3 weeks. Cough-variant asthma (n=30) and cough-predominant asthma (n=7) were treated with ICS/LABA. There was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma and cough-predominant asthma between medium and high doses (14.3% versus 10.9%, respectively) (p=0.192). Moreover, there was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma between medium and high doses (13.2% versus 11.5%, respectively) (p=0.433). The medium starting dose of ICS/LABA is sufficient for treating cough-variant asthma.